MapLight Therapeutics, Inc.(MPLT)Earnings, Financials & Key Ratios
MPLT•NASDAQ
$29.29
$1.33B mkt cap·Price updated May 14, 2026
- Revenue$0
- EBITDA-$82M-45.0%
- Net Income-$78M-39.3%
- EPS (Diluted)-1.87-39.6%
- ROE-83.21%+31.2%
- ROIC-153.68%
- Debt/Equity0.06-31.3%
MPLT Key Insights
MapLight Therapeutics, Inc. (MPLT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Expensive at 10.5x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MPLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MPLT Price & Volume
MapLight Therapeutics, Inc. (MPLT) stock price & volume — 10-year historical chart
Loading chart...
MPLT Growth Metrics
MapLight Therapeutics, Inc. (MPLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-103.74%
5 Years-103.74%
3 Years-103.74%
Last Year-83.91%
MPLT Recent Earnings
MapLight Therapeutics, Inc. (MPLT) EPS & revenue vs analyst estimates — last 2 quarters
●Beat EPS 0/2 qtrs (0%)
Q2 2026Latest
Mar 26, 2026EPS
$2.47
Est $1.05
-135.2%
Revenue
—
Q4 2025
Dec 4, 2025EPS
$37.18
Est $1.72
-2061.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $2.47vs $1.05-135.2% | — |
| Q4 2025 | Dec 4, 2025 | $37.18vs $1.72-2061.6% | — |
Based on last 2 quarters of dataView full earnings history →
MPLT Peer Comparison
MapLight Therapeutics, Inc. (MPLT) competitors in industry — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACNB | 544.49M | 52.59 | 14.61 | 28.89% | 9.2% | 0.78 | ||
 PTGX | 6.79B | 105.55 | -51.49 | -89.41% | -6.48% | -17.76% | 0.02 | |
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 NRXP | 88.86M | 3.21 | -2.40 | -157.28% | ||||
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ACAD | 3.78B | 22.09 | 9.65 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.69B | 22.86 | 6.93 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare MPLT vs Peers
MapLight Therapeutics, Inc. (MPLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MPLT Income Statement
MapLight Therapeutics, Inc. (MPLT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 574K | 556K | 701K | 438K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | -574K▲ 0% | -556K▲ 3.1% | -701K▼ 26.1% | -438K▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | 3.14% | -26.08% | - |
| Operating Expenses | 30.67M | 56.73M | 82.25M | 108.18M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 4.1M | 7.61M | 14.42M | 14.04M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 26.57M | 49.12M | 67.82M | 94.14M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -31.25M▲ 0% | -57.28M▼ 83.3% | -82.95M▼ 44.8% | -108.48M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -83.33% | -44.8% | - |
| EBITDA | -30.67M | -56.73M | -82.25M | -107.85M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -84.95% | -44.99% | - |
| D&A (Non-Cash Add-back) | 574K | 556K | 701K | 632K |
| EBIT | -30.02M | -55.71M | -77.58M | -106.46M |
| Net Interest Income | 429K | 1.1M | 4.5M | 3.95M |
| Interest Income | 429K | 1.1M | 4.5M | 3.95M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.23M | 1.57M | 5.37M | 5.65M |
| Pretax Income | -30.02M▲ 0% | -55.71M▼ 85.6% | -77.58M▼ 39.3% | -102.83M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -30.02M▲ 0% | -55.71M▼ 85.6% | -77.58M▼ 39.3% | -102.83M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -85.6% | -39.26% | - |
| Net Income (Continuing) | -30.02M | -55.71M | -77.58M | -102.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.72▲ 0% | -1.34▼ 86.1% | -1.87▼ 39.6% | -2.48▲ 0% |
| EPS Growth % | - | -86.11% | -39.55% | - |
| EPS (Basic) | -0.72 | -1.34 | -1.87 | - |
| Diluted Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M |
| Basic Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M |
| Dividend Payout Ratio | - | - | - | - |
MPLT Balance Sheet
MapLight Therapeutics, Inc. (MPLT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 32.03M | 83.6M | 114.6M | 245.31M |
| Cash & Short-Term Investments | 27.66M | 79.77M | 108.8M | 227.17M |
| Cash Only | 27.66M | 79.77M | 38.25M | 64.15M |
| Short-Term Investments | 0 | 0 | 70.54M | 163.02M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 4.37M | 0 | 0 | 18.14M |
| Total Non-Current Assets | 7.36M | 7.8M | 22.31M | 11.92M |
| Property, Plant & Equipment | 7.12M | 6.58M | 7.56M | 6.57M |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 234K | 1.22M | 11.59M | 14.49M |
| Other Non-Current Assets | 0 | 0 | 3.17M | 15.74M |
| Total Assets | 39.39M▲ 0% | 91.41M▲ 132.1% | 136.92M▲ 49.8% | 257.22M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 132.07% | 49.78% | -42.06% |
| Total Current Liabilities | 12.6M | 14.7M | 15.92M | 18.56M |
| Accounts Payable | 3.6M | 3.25M | 1.91M | 2.45M |
| Days Payables Outstanding | 2.29K | 2.13K | 995.55 | 1.53K |
| Short-Term Debt | 348K | 495K | 778K | 0 |
| Deferred Revenue (Current) | 5.86M | 4.2M | 3.24M | 10.09M |
| Other Current Liabilities | 1.34M | 4M | 5.98M | 4M |
| Current Ratio | 2.54x | 5.69x | 7.20x | 7.20x |
| Quick Ratio | 2.54x | 5.69x | 7.20x | 7.20x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 5.92M | 5.43M | 5.8M | 5.14M |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 5.92M | 5.43M | 5.8M | 21.91M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 308.82M |
| Total Liabilities | 18.52M | 20.13M | 21.72M | 23.7M |
| Total Debt | 6.27M | 5.92M | 6.58M | 6.01M |
| Net Debt | -21.39M | -73.84M | -31.67M | -58.14M |
| Debt / Equity | 0.30x | 0.08x | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | 0.54x |
| Interest Coverage | - | - | - | - |
| Total Equity | 20.87M▲ 0% | 71.28M▲ 241.6% | 115.19M▲ 61.6% | 233.52M▲ 0% |
| Equity Growth % | - | 241.55% | 61.6% | -46.19% |
| Book Value per Share | 0.50 | 1.72 | 2.78 | 5.64 |
| Total Shareholders' Equity | 20.87M | 71.28M | 115.19M | 233.52M |
| Common Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -66.08M | -121.79M | -199.37M | -280.97M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 163K | 46K |
| Minority Interest | 0 | 0 | 0 | 0 |
MPLT Cash Flow Statement
MapLight Therapeutics, Inc. (MPLT) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -26.58M | -52.01M | -78.81M | -78.81M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -95.68% | -51.55% | -28.13% |
| Net Income | -30.02M | -55.71M | -77.58M | -102.83M |
| Depreciation & Amortization | 574K | 556K | 701K | 632K |
| Stock-Based Compensation | 0 | 0 | 0 | 339K |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 703K |
| Working Capital Changes | 1.72M | 2.04M | -3.06M | -11.64M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 144K |
| Cash from Investing | -746K | -462K | -80.79M | -48.26M |
| Capital Expenditures | -746K | -462K | -770K | -203K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 33.17M | 104.57M | 118.06M | 197.86M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1.01M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -2.19M | -1.02M |
| Net Change in Cash | 27.66M▲ 0% | 52.1M▲ 88.3% | -41.52M▼ 179.7% | 75.06M▲ 0% |
| Free Cash Flow | -27.32M▲ 0% | -52.47M▼ 92.0% | -79.58M▼ 51.7% | -113M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -92.03% | -51.68% | - |
| FCF per Share | -0.66 | -1.27 | -1.92 | -1.92 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.93x | 1.02x | 1.10x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
MPLT Key Ratios
MapLight Therapeutics, Inc. (MPLT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | -120.91% | -83.21% | -209.17% |
| Return on Invested Capital (ROIC) | - | -153.68% | -153.68% |
| Debt / Equity | 0.08x | 0.06x | 0.06x |
| FCF Conversion | 0.93x | 1.02x | 1.10x |
MPLT Frequently Asked Questions
MapLight Therapeutics, Inc. (MPLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MapLight Therapeutics, Inc. (MPLT) grew revenue by 0.0% over the past year. Growth has been modest.
MapLight Therapeutics, Inc. (MPLT) reported a net loss of $102.8M for fiscal year 2024.
Dividend & Returns
MapLight Therapeutics, Inc. (MPLT) has a return on equity (ROE) of -83.2%. Negative ROE indicates the company is unprofitable.
MapLight Therapeutics, Inc. (MPLT) had negative free cash flow of $113.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More MPLT
MapLight Therapeutics, Inc. (MPLT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates